Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach
Inflammatory Bowel Diseases · 03.06.2024 · 30 (6) · 1018-1031
DOI: 10.1093/ibd/izad229 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 06.10.2023. Verfasst von Angelo Del Gaudio und 6 weiteren Autor:innen. Beteiligte Einrichtung: UOS Malattie Infiammatorie Croniche Intestinali, Centro di Malattie dell'Apparato Digerente (CEMAD), Fondazione Policlinico Universitario A. Gemelli …. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Colitis. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recently, antitumor immunotherapies have witnessed a breakthrough with the emergence of immune checkpoint inhibitors (ICIs) including programmed cell death-1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors. Unfortunately, the use of ICIs has also led to the advent of a novel class of adverse events that differ from those of classic chemotherapeutics and are more reminiscent of autoimmune diseases, the immune-related adverse events (IRAEs). Herein, we performed an insight of the main IRAEs associated with ICIs, focusing on gastroenterological IRAEs and specifically on checkpoint inhibitor colitis, which represents the most widely reported IRAE to date. We comprehensively dissected the current evidence regarding pathogenesis, diagnosis, and management of ICIs-induced colitis, touching upon also on innovative therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UOS Malattie Infiammatorie Croniche Intestinali, Centro di Malattie dell'Apparato Digerente (CEMAD), Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, 00168, Italy.
- UOC di Medicina Interna e Gastroenterologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, 00168, Italy.
- Department of Pathology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, 00168, Italy.
- Department of Medicine and Ageing Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, 66100, Italy.
- Center for Advanced Studies and Technology (CAST), "G. d'Annunzio" University of Chieti-Pescara, Chieti, 66100, Italy.
ORCID-Profile: Federica Di Vincenzo, Valentina Petito, Franco Scaldaferri
Zitieren
APA
Del Gaudio, A., Di Vincenzo, F., Petito, V., Giustiniani, M. C., Gasbarrini, A., Scaldaferri, F., & Lopetuso, L. R. (2024). Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach. Inflammatory Bowel Diseases, 30(6), 1018-1031. https://doi.org/10.1093/ibd/izad229
Vancouver
Del Gaudio A, Di Vincenzo F, Petito V, Giustiniani MC, Gasbarrini A, Scaldaferri F, et al. Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach. Inflammatory Bowel Diseases. 2024;30(6):1018-1031. doi:10.1093/ibd/izad229
BibTeX
@article{DelGaudio2024,
author = {Del Gaudio, Angelo and Di Vincenzo, Federica and Petito, Valentina and Giustiniani, Maria Cristina and Gasbarrini, Antonio and Scaldaferri, Franco and Lopetuso, Loris Riccardo},
title = {Focus on Immune Checkpoint Inhibitors-related Intestinal Inflammation: From Pathogenesis to Therapeutical Approach},
journal = {Inflammatory Bowel Diseases},
year = {2024},
volume = {30},
number = {6},
pages = {1018--1031},
doi = {10.1093/ibd/izad229}
}
EUVIMED